This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Covid toe (toes)

Authoring team

Chilblain-like lesions or 'COVID toes' are acral lesions described as erythematous to purple purpuric macules, papules, and/or vesicles that predominantly involve the feet, and to a lesser extent, the hands (1).

Histologically, chilblains is an inflammatory disorder showing dermal edema along with a superficial and deep perivascular lymphocytic infiltrate (2).

Cases of acral lesions resembling chilblains have been reported worldwide at a higher rate than before the pandemic, becoming one of the most commonly reported cutaneous manifestations during the pandemic (1).

It is hypothesised that a robust antiviral immune response in young patients may truncate the clinical course and induce microangiopathic changes that could lead to chilblain-like skin lesions.

  • Patients present with chilblain-like lesions only after a successful viral response is mounted and lesions are detected only when symptoms are likely to be subsiding (2).

Click here further information and images of "COVID" toes.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.